Relay Therapeutics, Inc.

RLAY · Healthcare

$18.49

Capitalización: 4.05B USDRendimiento por dividendo: —
Advance¿Es buen momento para comprar Relay Therapeutics, Inc.? Pregunta a Copenvest AIObtén una lectura Advance con IA sobre timing, riesgo y qué hacen los inversores rastreados.Preguntar a Copenvest AI

Cargando gráfico…

Noticias

Últimos titulares de esta acción

GlobeNewswire Inc.1 sept 2026, 20:46

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

Relay Therapeutics announced that management will participate in fireside chats at the Wells Fargo Healthcare Conference on September 8, 2026 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The clinical-stage precision medicine company is developing therapies for cancer and genetic diseases, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer.